Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Margaret A. Tempero(University of California, San Francisco), Mokenge P. Malafa(Moffitt Cancer Center), Mahmoud M. Al-Hawary(University of Michigan–Ann Arbor), Horacio J. Asbun(Mayo Clinic in Arizona), Andrew Bain(Roswell Park Comprehensive Cancer Center), Stephen W. Behrman(University of Tennessee Health Science Center), Al B. Benson, Ellen F. Binder(Washington University in St. Louis), Dana B. Cardin(Vanderbilt University), Charles Cha(Yale Cancer Center), E. Gabriela Chiorean(Seattle Cancer Care Alliance), Vincent Chung(City Of Hope National Medical Center), Brian G. Czito(Cancer Institute (WIA)), Mary Dillhoff(The Ohio State University), Efrat Dotan(Fox Chase Cancer Center), Cristina R. Ferrone(Harvard University Press), Jeffrey M. Hardacre(Case Western Reserve University), William G. Hawkins(Washington University in St. Louis), Joseph M. Herman(The University of Texas MD Anderson Cancer Center), Andrew H. Ko(University of California, San Francisco), Srinadh Komanduri, Albert C. Koong(Stanford University), Noelle K. LoConte, Andrew M. Lowy(Moores Cancer Center), Cassadie Moravek(Pancreatic Cancer Action Network), Eric K. Nakakura(University of California, San Francisco), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Jorge Obando(Duke Medical Center), Sushanth Reddy(University of Alabama at Birmingham), Courtney L. Scaife(University of Utah), Sarah P. Thayer(Fred and Pamela Buffett Cancer Center), Colin D. Weekes(University of Colorado Denver), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Brian M. Wolpin, Jennifer L. Burns, Susan Darlow
Cited by 1,028
Abstract
Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.
Related Papers
No related papers found
Powered by citation graph analysis